Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04115488

Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® — Antelope  

Relapsing-Remitting Multiple Sclerosis (RRMS) Clinical Trial

Official title:
Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)

Clinical Trial Summary

This is a multi-center, randomized, parallel arm, double-blind study with a total duration of subjects' participation of 48 weeks. Approximately 260 participants with relapsing-remitting multiple sclerosis will be randomized to receive 12 doses of either PB006 or EU-licensed Natalizumab.

Clinical Trial Description

This is a Phase 3 multicenter, double-blind, active-controlled, randomized, parallel-group study to assess the equivalence in efficacy and similarity in safety of biosimilar PB006 compared to Tysabri in patients with RRMS. All eligible patients will be randomly assigned to one of two treatment groups in a 1:1 ratio, to receive a total of twelve intravenous (IV) infusion of either PB006 or Tysabri at a dose of 300 mg at each intravenous (IV) infusion administered with every single one intravenous (IV) infusion administered every 4 weeks of either PB006 or Tysabri at a dose of 300 mg starting at visit 1 (week 0) through visit 12 (week 44), for a total of 12 infusions. The End-of-Study Visit (visit 13, week 48) will be performed 4 weeks after the last infusion ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04115488
Study type Interventional
Source Polpharma Biologics S.A.
Contact
Status Completed
Phase Phase 3
Start date October 1, 2019
Completion date February 7, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05177523 - Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Withdrawn NCT05172466 - Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab N/A
Completed NCT05304520 - A Study for Tysabri Participant Preference
Recruiting NCT06430671 - Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis Phase 1/Phase 2
Recruiting NCT05811416 - A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
Active, not recruiting NCT03846219 - MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) Phase 2
Completed NCT02587065 - Plegridy Satisfaction Study in Participants Phase 4
Not yet recruiting NCT02568111 - Brimonidine Tartrate for the Treatment of Injection Related Erythema Phase 4
Terminated NCT01633112 - MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone Phase 3
Completed NCT01738347 - Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). Phase 1
Terminated NCT02881567 - Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab Phase 3
Not yet recruiting NCT05245344 - Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study